Sangeetha Sundaramoorthy has submitted to the Exchange a copy of Disclosures under Regulation 10(6)-Report to stock Exchange in respect of any acquisition made in reliance upon exemption provided for in regulation 10 of SEBI (SAST) Regulations, 2011
LOTUSEYE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.9 pts more than Nifty Microcap 250 and 4.5 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sangeetha Sundaramoorthy, a promoter of Lotus Eye Hospital, acquired 14,28,571 shares (6.87% of diluted share capital) from fellow promoter Kavetha Sundaramoorthy at Rs. 70 per share via a Share Purchase Agreement dated June 2, 2025, with the transaction executed on February 27, 2026. The acquirer's stake rose from 28.14% (58,51,901 shares) to 35.01% (72,80,472 shares), while the seller's stake fell from 9.61% (19,99,564 shares) to 2.75% (5,70,993 shares). The transfer qualifies for an exemption from making an open offer under Regulation 10(1)(a)(i), which covers inter-se transfers among promoters. The combined promoter shareholding remains broadly unchanged at around 37.76%, as this is a reshuffle within the promoter group rather than a change in overall promoter control.
No change in total promoter ownership or control of the company — the stock price is unlikely to be materially affected since the shares merely shifted between two promoters. Shareholders should note that the acquirer's individual holding crossed 35%, though it remains well below any open-offer trigger threshold.